

Prof. Mahmoud Suleiman

15. PUBLICATIONS

15.1 Theses

15.2 Refereed papers in professional journals

Published papers

Accepted (or in press) papers

Submitted papers

Basic research

1. **Suleiman M**, Kapeliovich M, Roguin A, Aronson D, Meisel SR, Shochat M, Reisner S, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin type and 30-day mortality in diabetic individuals presenting with acute myocardial infarction. *Diabetes Care*. 2003; 26(9):2699-700. Q1, H index 364
2. **Suleiman M**, Asleh R, Cabantchik ZI, Breuer W, Levy AP. Serum labile plasma iron is an independent and powerful predictor of mortality after myocardial infarction in individuals with diabetes mellitus. *Diabetes Care*. 2004; 27(11):2730-2732. Q1, H index 364
3. **Suleiman M**, Aronson D, Kapeliovich MR, Roguin R, Meisel SR, Shochat M, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin Polymorphism Predicts 30-Day Mortality and Heart Failure in Patients with Diabetes and Acute Myocardial Infarction. *Diabetes*. 2005; 54(9):2802-2806. Q1, H index 320

Clinical research

1. **Suleiman M**, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R. Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Eptifibatide and Abciximab: Outcomes, Complications and Thrombocytopenia During Percutaneous Coronary Intervention. *J Invasive Cardiol*. 2003; 15(6):319-323. Q2, H index 55
2. Nikolsky E, Gruberg L, Pechersky S, Kapeliovich M, Grenadier E, Amikam S, Boulos M, **Suleiman M**, Markiewicz W, Beyar R. Stent deployment failure: Reasons, implications, and shortand long-term outcomes. *Catheter Cardiovasc Interv*. 2003 ;59(3):324-8. Q2, h index 112
3. **Suleiman M**, Aronson D, Reisner S, Kapeliovich M, Markiewicz W, Levy Y, Hammerman H, Admission C-Reactive Protein is a Strong Independent Predictor of 30-Day Mortality in Patients with Acute Myocardial Infarction. *Am J Med*. 2003; 115(9):695-70. Q1, H index 223
4. **Suleiman M**, Kapeliovich M, Roguin A, Aronson D, Meisel SR, Shochat M, Reisner S, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin type and 30-day mortality in

- diabetic individuals presenting with acute myocardial infarction. *Diabetes Care*. 2003; 26(9):2699-700. Q1, H index 364
- 5.**Suleiman M**, Asleh R, Cabantchik ZI, Breuer W, Levy AP. Serum labile plasma iron is an independent and powerful predictor of mortality after myocardial infarction in individuals with diabetes mellitus. *Diabetes Care*. 2004; 27(11):2730-2732. Q1, H index 364
- 6.**Suleiman M**, Hammerman H, Boulous M, Kapeliovich MR, Suleiman A, Agmon Y, Markiewicz W, Aronson D. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. *Circulation*. 2005 ; 111(6):754-760. Q1, H index 593
- 7.**Suleiman M**, Aronson D, Kapeliovich MR, Roguin R, Meisel SR, Shochat M, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin Polymorphism Predicts 30-Day Mortality and Heart Failure in Patients with Diabetes and Acute Myocardial Infarction. *Diabetes*. 2005; 54(9):2802-2806. Q1, H index 320
- 8.**Suleiman M**, Khatib R, Mahamid R, Boulous M, Kapeliovich M.R, Levy Y, Hammerman H, Markiewicz W, Aronson D. Early Inflammation and Risk of Long-Term Development of Heart Failure and Mortality in Survivors of Acute Myocardial Infarction: Predictive Role of C-Reactive Protein. *J Am Coll Cardiol*. 2006; 47:962-968. Q1, H index 419
- 9.Gruberg L, **Suleiman M**, Kapeliovich M, Hammerman H, Grenadier E, Boulous M, Amikam S, Markiewicz W, Beyar R. Glycoprotein IIb/IIIa Inhibitors during Rescue Percutaneous Coronary Intervention in Acute Myocardial Infarction. *J Invasive Cardiol*. 2006; 18:59–62. Q2, H index 55
- 10.Goldsher D, Amikam S, Boulous M, **Suleiman M**, Shreiber R, Eran A, Goldshmid Y, Mazbar R, Roguin A. Magnetic Resonance Imaging for Patients with Permanent Pacemakers: Initial Clinical Experience. *Isr Med Assoc J*. 2006; 8:91–94. Q3, H index 53
- 11.Dragu R, Huri S, Zuckerman R, **Suleiman M**, Mutlak D, Agmon Y, Kapeliovich MR, Beyar R, Markiewicz W, Hammerman H, Aronson D. Predictive value of white blood cell subtypes for longterm outcome following myocardial infarction. *Atherosclerosis*. 2008; 196(1):405-412. Q1, H index 166
- 12.**Suleiman M**, Gepstein L, Roguin A, Beyar R, Boulous M. Catheter ablation of cardiac arrhythmias guided by electroanatomic imaging (CARTO): a single-center experience. *Isr Med Assoc J*. 2007; 9(4):260-264. Q3, H index 53
- 13.Aronson D, Hammerman H, Kapeliovich MR, Suleiman A, Agmon Y, Beyar R, Markiewicz W, **Suleiman M**. Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function. *Diabetes Care*. 2007; 30(4):960- 966. Q1, H index 364
- 14.Aronson D, **Suleiman M**, Agmon Y, Suleiman A, Blich M, Kapeliovich MR, Beyar R, Markiewicz W, Hammerman H. Changes in haemoglobin levels during hospital course and longterm outcome after acute myocardial infarction. *Eur Heart J*. 2007; 28(11):1289-1296. Q1, H index 286
- 15.Glikson M, **Suleiman M**, Luria DM, Martin ML, Hodge DO, Shen WK, Bradley DJ, Munger TM, Rea RF, Hayes DL, Hammill SC, Friedman PA. Do Abandoned Leads Pose Risk to ICD Patients? *Heart Rhythm*. 2009; 6(1):65-68. Q1, H index 125
- 16.Aronson D, Hammerman H, **Suleiman M**, Markiewicz W. Usefulness of changes in fasting glucose during hospitalization to predict long-term mortality in patients with acute

- myocardial infarction. *Am J Cardiol.* 2009; 104(8):1013-7. Q1, h index 215
17. AbouEzzeddine O, Suleiman M, Buescher T, Friedman PA, Jahangir A, Mears JA, Ladwing DJ, Munger TM, Hammill SC, Packer DL, Asirvatham SJ. Relevance of endocavitary structures in ablation procedures for ventricular tachycardia. *J Cardiovasc Electrophysiol.* 2010; 21(3):245-254. Q1, H index 135
18. Blich M, **Suleiman M**, Zeidan Shwiri T, Marai I, Boulos M, Amikam S. Long term outcome of VDD mode pacing in patients with atrioventricular block using a single lead. *Clin Cardiol.* 2010; 33(1):18-22. Q1, H index 70
19. Marai I, **Suleiman M**, Blich M, Zeidan-Shwiri T, Gepstien L, Boulos M. Clinical and Electrophysiologic Outcomes of Patients Undergoing Percutaneous Endocardial Ablation of Scar – Related Ventricular Tachycardia: Single Center Experience. *Isr Med Assoc J.* 2010;12(11):667-70. Q3, H index 53
20. Zeidan-Shwiri T, Aronson D, Atalla K, Blich M, **Suleiman M**, Marai I, Gepstein L, Lavie L, Lavie P, Boulos M. Circadian pattern of life-threatening ventricular arrhythmia in patients with sleep-disordered breathing and implantable cardioverter-defibrillators. *Heart Rhythm.* 2011;8(5):657-62. Q1, H index 125
21. **Suleiman M**, Brady PA, Asirvatham SJ, Friedman PM, Munger TM. The Non-Coronary Cusp as a Site for Successful Ablation of Accessory Pathways – Electrogram Characteristics in Three Cases. *J Cardiovas Electrophysiology. J Cardiovasc Electrophysiol.* 2011;22(2):203-9. Q1, H index 135
22. Eliyahu S, Roguin A, Kerner A, Boulos M, Lorber A, Halabi M, **Suleiman M**, Nikolsky E, Rispler S, Beyar R. Patient safety and outcomes from live case demonstrations of interventional cardiology procedures. *JACC Cardiovasc Interv.* 2012;5(2):215-24. Q1, H index 116.
23. Marai I, Khoury A, **Suleiman M**, Gepstein L, Blich M, Lorber A, Boulos M. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. *Am J Cardiol.* 2012;110(1):72-6. Q1, H index 215
24. Khoury A, Marai I, **Suleiman M**, Blich M, Lorber A, Gepstein L, Boulos M. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm.* 2013;10(11):1671-5. Q1, H index 125
25. **Suleiman M**, Goldenberg I, Haim M, Schliamser JE, Boulos M, Ilan M, Swissa M, GavrielovYusim N, Fuchs T, Amit G, Glikson M; Israeli Working Group on Pacing and Electrophysiology. Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverterdefibrillator or cardiac resynchronization therapy in a real-world setting: data from the Israeli ICD Registry. *Heart Rhythm.* 2014;11(3):435-41. Q1, H index 125
26. Arnson Y, **Suleiman M**, Glikson M, Sela R, Geist M, Amit G, Schliamser JE, Goldenberg I, Ben-Zvi S, Orvin K, Rosenheck S, Adam Freedberg N, Strasberg B, Haim M. Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry. *Heart Rhythm.* 2014;11(5):814-21. (#Equal contribution). Q1, H index 125
27. Amit G, **Suleiman M**, Konstantino Y, Luria D, Kazatsker M, Chetboun I, Haim M,

GavrielovYusim N, Goldenberg I, Glikson M; On behalf of the Israeli Working Group on Pacing and Electrophysiology. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry. *Europace*. 2014;16(8):1175-80. Q1, H index 99

28.Eisen A, **Suleiman M**, Strasberg B, Sela R, Rosenheck S, Freedberg NA, Geist M, Ben-Zvi S, Goldenberg I, Glikson M, Haim M. Renal Dysfunction and Clinical Outcomes of Patients Undergoing ICD and CRTD Implantation: Data from the Israeli ICD Registry. *J Cardiovasc Electrophysiol*. 2014; 25(9):990-7. (#Equal contribution). Q1, H index 135

29.**Suleiman M**, Goldenberg I, Samniah N, Rosso R, Marai I, Pekar A, Steiner H, Khalameizer V, Militianu A, Glikson M. Outcome of Patients with Advanced Heart Failure Who Receive DeviceBased Therapy for Primary Prevention of Sudden Cardiac Death: Insights from the Israeli ICD Registry. *Pacing Clin Electrophysiol*. 2015; 38(6):738-45. Q2, H index 98

30.Sabbag A, **Suleiman M**, Glick A, Fuchs T, Medina A, Golovchiner G, Steiner H, Goldenberg I, Glikson M, Beinart R. Ethnic differences among implantable cardioverter defibrillators recipients in Israel. *Am J Cardiol*. 2015 ;115(8):1102-6. Q1, H index 215

31.Blich M, Marai I, **Suleiman M**, Lorber A, Gepstein L, Boulous M, Khoury A. Electrocardiographic comparison of ventricular premature complexes during exercise test in patients with CPVT and healthy subjects. *Pacing Clin Electrophysiol*. 2015;38(3):398-402. Q2, H index 98

32.Sabbag A, **Suleiman M**, Laish-Farkash A, Samania N, Kazatsker M, Goldenberg I, Glikson M, Beinart R; Israeli Working Group of Pacing and Electrophysiology. Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry. *Heart Rhythm*. 2015;12(12):2426-33. Q1, H index 125

33.Blich M, Efrati E, Marai I, **Suleiman M**, Gepstein L, Boulous M. Novel Clinical Manifestation of the Known SCN5A D1790G Mutation. *Cardiology*. 2015;132(4):228-32.

34.Soucek F, Covassin N, Singh P, Ruzek L, Kara T, **Suleiman M**, Lerman A, Koestler C, Friedman PA, Lopez-Jimenez F, Somers VK. Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation. *Am J Cardiol*. 2015;116(9):1443-6. Q1, H index 215

35.Laish-Farkash A, **Suleiman M**. Primary Versus Secondary Atrial Fibrillation: Is it Time for a Different Classification of Atrial Fibrillation? *J Cardiovasc Electrophysiol*. 2015 Sep 22. doi: 10.1111/jce.12840. Q1, H index 135

36.Bogdan S, Nof E, Eisen A, Sela R, Rosenheck S, Freedberg N, Geist M, Ben-Zvi S, Haim M, Glikson M, Goldenberg I, **Suleiman M**; Israeli working group of pacing and electrophysiology of the Israeli Heart Society. Clinical Outcomes in Patients with Severe Renal Dysfunction Including Dialysis Following Defibrillator Implantation. *Am J Nephrol*. 2015;42(4):295-304. Q1, H index 80

37.Marai I, Boulous M, Lessick J, Abadi S, Blich M, **Suleiman M**. Outflow tract ventricular arrhythmia originating from the aortic cusps: our approach for challenging ablation. *J Interv Card Electrophysiol*. 2015 Nov 16. Q2, H index 52

38.Konstantino Y, Haim M, Boxer J, Goldenberg I, Feldman, Michowitz Y, Glikson M, **Suleiman M**. Clinical Outcomes of Single vs. Dual Chamber Implantable Cardioverter

Defibrillators: Lessons from the Israeli ICD Registry. *J Cardiovasc Electrophysiol*. 2016 Feb 8. doi: 10.1111/jce. Q1, H index 135

39.Marai I, **Suleiman M**, Blich M, Lessick J, Abadi S, Boulos M. Impact of computed tomography image and contact force technology on catheter ablation for atrial fibrillation. *World J Cardiol*. 2016;8(4):317-22. Q3

40.Matsuzawa Y, **Suleiman M**, Guddeti RR, Kwon TG, Monahan KH, Lerman LO, Friedman PA, Lerman A. Age-Dependent Predictive Value of Endothelial Dysfunction for Arrhythmia Recurrence Following Pulmonary Vein Isolation. *J Am Heart Assoc*. 2016 Sep 9;5(9). Q1, h index 72

41.Laish-Farkash A, Bruoha S, Katz A, Goldenberg I, **Suleiman M**, Michowitz Y, Shlomo N, Einhorn-Cohen M, Khalameizer V. Morbidity and mortality with cardiac resynchronization therapy with pacing vs. with defibrillation in octogenarian patients in a real-world setting. *Europace*. 2016 Oct 12. pii: euw238. Q1, H index 99

42.Steiner H, Geist M, Goldenberg I, **Suleiman M**, Glikson M, Tenenbaum A, Swissa M, Fisman EZ, Golovchiner G, Strasberg B, Barsheshet A; Israeli Working Group of Pacing and EP. Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry. *Cardiovasc Diabetol*. 2016 Dec 1;15(1):160. Q1, H index 70

43. Laish-Farkash A, **Suleiman M**. Comparison of the Efficacy of PVAC® and nMARQ™ for paroxysmal atrial fibrillation. *J Atr Fibrillation*. 2017 Apr 30;9(6):1550. Q3, H index 111

44.Goldenberg I, Barsheshet A, Laish-Farkash A, Swissa M, Schliamser JE, Michowitz Y, Glikson M, **Suleiman M**; Israeli Working Group on Pacing and Electrophysiology. Anemia and the Risk of Life-threatening Ventricular Tachyarrhythmias from the Israeli Implantable Cardioverter Defibrillator Registry. *Am J Cardiol*. 2017 Dec 15;120(12):2187-2192. Q1, h index 215

45.Dabbah S, Chertin L, Khateeb A, Rosenfeld I, **Suleiman M**, Halabi M. Red cell distribution width predicts death and appropriate therapy in patients with implantable cardioverter defibrillator: A simple measurement with prognostic value in a variety of diseases, may help in better selection of patients who will benefit the most from this device. *Pacing Clin Electrophysiol*. 2017 Dec;40(12):1384-1388. Q2, H index 98

46.Laish-Farkash A, **Suleiman M**. Evaluation of left atrial thrombus prior to catheter ablation of atrial fibrillation: Is it time for an individualized approach? *J Cardiovasc Electrophysiol*. 2017 Oct;28(10):1137-1139. Q1, h index 135

47.Laish-Farkash A, Bruoha S, Khalameizer V, Yosefy C, Michowitz Y, **Suleiman M**, Katz A. Multisite cardiac resynchronization therapy for traditional and non-traditional indications. *J Interv Card Electrophysiol*. 2018 Mar;51(2):143-152. Q2, H index 52

48.Leshem E, **Suleiman M**, Laish-Farkash A, Haim M, Geist M, Luria D, Glikson M, Goldenberg I, Michowitz Y; Israeli Working Group of Pacing and Electrophysiology. Impact of quadripolar LV leads on heart failure hospitalization rates among patients implanted with CRT-D: data from the Israeli ICD Registry. *J Interv Card Electrophysiol*. 2018 Jan;51(1):5-12. Q2, H index 52

49.Leshem E, Rahkovich M, Mazo A, **Suleiman M**, Blich M, Laish-Farkash A, Konstantino Y, Fogelman R, Strasberg B, Geist M, Chetboun I, Swissa M, Ilan M, Glick A, Michowitz Y, Rosso R, Glikson M, Belhassen B. Arrhythmic Events in Brugada Syndrome: A Nationwide

Israeli Survey of the Clinical Characteristics, Treatment; and Long-Term Follow-up (ISRABRU-VF). *Isr Med Assoc J*. 2018 May;20(5):269-276. Q3, H index 53

50. Sabbag A, Glikson M, **Suleiman M**, Boulos M, Goldenberg I, Beinart R, Nof E. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator. *Heart Rhythm*. 2019 Jun;16(6):813-819. Q1, H index 125

51. Goldenberg I, Mor T, Nof E, Younis A, Berkovitch A, Rosso R, Barsheshet A, **Suleiman M**, Beinart R. Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction. *Europace*. 2019 Mar 1;21(3):459-464. Q1, H index 99

52. Blich M, Khoury A, **Suleiman M**, Lorber A, Gepstein L, Boulous M. Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation. *Int Heart J*. 2019 Jul 27;60(4):979-982. Q2, H index 43

53. Ghersin I, Zahran M, Azzam ZS, **Suleiman M**, Bahouth F. Prognostic value of cardiac troponin levels in patients presenting with supraventricular tachycardias. *J Electrocardiol*. 2020 Sep 19;62:200-203. Q3, H index 59

54. Aguilar M, Yarnitsky J, Botzer L, Rubinstein V, Nakar E, Markides V, Derval N, Anselmino M, Winterfield J, Melby D, Marai I, **Suleiman M**, Meyer C, Zei PC. The advanced reference annotation algorithm: A novel approach to reference annotation for electroanatomic mapping. *Int J Heart Rhythm* 2019;4:48-54. Q3

Case reports

1. **Suleiman M**, Volfovitz E, Boulman N, Levy Y. Adult onset Still's disease as a cause of ARDS and acute respiratory failure. *Scand J Rheumatol* 2002; 31:181-183. Q1, H index 75
2. **Suleiman M**, Munger TM, Powel DB, Asirvatham SJ. Successful cryoablation in the noncoronary aortic cusp for a left anteroseptal accessory pathway. *J Interv Card Electrophysiol*. 2008; 23(3):205-21. Q2, H index 52
3. Habib A, Friedman PA, Cooper LT, **Suleiman M**, Asirvatham AJ. Cardiac calcified amorphous tumor in a patient presenting for ventricular tachycardia ablation: intracardiac echocardiogram diagnosis and management. *J Interv Card Electrophysiol*. 2009; 2. Q2, H index 52
4. Marai I, **Suleiman M**, Lorber A, Boulos M. Iatrogenic intra-atrial macro-reentrant tachycardia following transcatheter closure of atrial septal defect treated by radiofrequency ablation. *Ann Pediatr Cardiol*. 2011;4(2):192-4. Q3
5. Marai I, Koskosi M, Keidar Z, **Suleiman M** and Samia Massalha. QTc Prolongation after a Negative Dipyridamole Pharmacological Stress Study. *Cardiol Pharmacol*. 2013; 3: 114
6. Marai I, Gepstein L, Boulos M, **Suleiman M**. Ablation of Idiopathic Ventricular Fibrillation Triggered by Ventricular Premature Beat Originating from Myocardium of Right Ventricle: Case report. *Journal of Cardiology Cases*. 2014; 9 (3):109-112. Q4

Review papers

1. **Suleiman M**, Asirvatham SJ. Ablation above the Semilunar Valves: When, Why, and

How?. Part I. Heart Rhythm. 2008; 5(10):1485-1492. Q1, H index 125

2.**Suleiman M**, Asirvatham SJ. Ablation above the Semilunar Valves: When, Why, and How?. Part II. Heart Rhythm. 2008; 5(11):1625-1630. Q1, H index 125

3.**Suleiman M**, Aronson D. Impact of Atrial Fibrillation on cardiovascular mortality in the setting of myocardial infarction. Journal of atrial fibrillation. 2013;5(4):39-48. Q3

15.3 Books

15.4 Book chapters

15.5 Letters to the Editor

15.6 Refereed papers in conference proceedings

15.7 Patents (granted)

15.8 Other publications